Relay Therapeutics Inc. leverages its proprietary Dynamo platform to analyze protein motion and design small-molecule drugs for previously intractable targets. The company's pipeline is primarily focused on precision oncology and genetic diseases, targeting specific genetic mutations. Its lead clinical candidates include zovegalisib (RLY-2608), a pan-mutant and isoform-selective PI3K alpha inhibitor for breast cancer and vascular anomalies, and RLY-8161 for NRAS-driven solid tumors. As a clinical-stage biotechnology firm, Relay does not yet generate commercial product revenue, instead funding its operations through capital markets and strategic partnerships with larger pharmaceutical companies like Pfizer and Genentech. Headquartered in Cambridge, Massachusetts, the company aims to address significant unmet medical needs in cancer treatment.
